Taysha Gene Therapies Inc Forecast, price target & analysts
Taysha Gene Therapies Inc Target price 2025 - Analyst rating & recommendation
Taysha Gene Therapies Inc Classifications & Recommendation:
Taysha Gene Therapies Inc Price Target
| Target Price | $6.55 |
| Price | $1.59 |
| Potential |
311.95%
register free of charge
|
| Number of Estimates | 10 |
|
10 Analysts have issued a price target Taysha Gene Therapies Inc 2026 .
The average Taysha Gene Therapies Inc target price is $6.55.
This is
311.95%
register free of charge
$8.00
403.14%
register free of charge
$5.00
214.47%
register free of charge
|
|
| A rating was issued by 11 analysts: 11 Analysts recommend Taysha Gene Therapies Inc to buy, 0 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Taysha Gene Therapies Inc stock has an average upside potential 2026 of
311.95%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 8.33 | 5.80 |
| 46.08% | 30.39% | |
| EBITDA Margin | -1,024.97% | -1,627.92% |
| 126.23% | 58.83% | |
| Net Margin | -885.70% | -1,248.74% |
| 30.45% | 40.99% |
11 Analysts have issued a sales forecast Taysha Gene Therapies Inc 2025 . The average Taysha Gene Therapies Inc sales estimate is
This results in the following potential growth metrics:
2 Analysts have issued an Taysha Gene Therapies Inc EBITDA forecast 2025. The average Taysha Gene Therapies Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
3 Taysha Gene Therapies Inc Analysts have issued a net profit forecast 2025. The average Taysha Gene Therapies Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.36 | -0.35 |
| 62.50% | 2.78% | |
| P/E | negative | |
| EV/Sales | 43.17 |
3 Analysts have issued a Taysha Gene Therapies Inc forecast for earnings per share. The average Taysha Gene Therapies Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the Taysha Gene Therapies Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Taysha Gene Therapies Inc...
Current Taysha Gene Therapies Inc Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Needham | Locked ➜ Locked | Locked | Feb 27 2025 |
| Chardan Capital | Locked ➜ Locked | Locked | Feb 26 2025 |
| Needham | Locked ➜ Locked | Locked | Jan 06 2025 |
| Canaccord Genuity | Locked ➜ Locked | Locked | Nov 15 2024 |
| Cantor Fitzgerald | Locked ➜ Locked | Locked | Nov 14 2024 |
| Chardan Capital | Locked ➜ Locked | Locked | Nov 14 2024 |
| Needham | Locked ➜ Locked | Locked | Nov 14 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Needham: Locked ➜ Locked
|
Feb 27 2025 |
|
Locked
Chardan Capital: Locked ➜ Locked
|
Feb 26 2025 |
|
Locked
Needham: Locked ➜ Locked
|
Jan 06 2025 |
|
Locked
Canaccord Genuity: Locked ➜ Locked
|
Nov 15 2024 |
|
Locked
Cantor Fitzgerald: Locked ➜ Locked
|
Nov 14 2024 |
|
Locked
Chardan Capital: Locked ➜ Locked
|
Nov 14 2024 |
|
Locked
Needham: Locked ➜ Locked
|
Nov 14 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
